Huang J - Search Results

1

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.

Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, Lordick F, Van Cutsem E, Gallego Plazas J, Huang J, Shen L, Oh SC, Sunpaweravong P, Soo Hoo HF, Turk HM, Oh M, Park JW, Moran D, Bhattacharya P, Arozullah A, Xu RH. Shah MA, et al. Among authors: huang j. Nat Med. 2023 Aug;29(8):2133-2141. doi: 10.1038/s41591-023-02465-7. Epub 2023 Jul 31. Nat Med. 2023. PMID: 37524953 Free PMC article. Clinical Trial.

2

A phase Ib/II study of fruquintinib in combination with paclitaxel as the second-line therapy for advanced gastric cancer.

Zhang Y, Wang ZX, Shen L, Li J, Huang J, Su WG, Zhang DS, Xu RH. Zhang Y, et al. Among authors: huang j. Cancer Commun (Lond). 2023 Jan;43(1):150-153. doi: 10.1002/cac2.12379. Epub 2022 Nov 4. Cancer Commun (Lond). 2023. PMID: 36331272 Free PMC article. No abstract available.

3

First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial.

Song Y, Zhang B, Xin D, Kou X, Tan Z, Zhang S, Sun M, Zhou J, Fan M, Zhang M, Song Y, Li S, Yuan Y, Zhuang W, Zhang J, Zhang L, Jiang H, Gu K, Ye H, Ke Y, Li J, Wang Q, Zhu J, Huang J; ASTRUM-007 investigators. Song Y, et al. Among authors: huang j. Nat Med. 2023 Feb;29(2):473-482. doi: 10.1038/s41591-022-02179-2. Epub 2023 Feb 2. Nat Med. 2023. PMID: 36732627 Free PMC article. Clinical Trial.

4

Perioperative treatment and biomarker analysis of LP002, an anti-PD-L1 antibody, plus chemotherapy in resectable gastric and gastroesophageal junction cancer.

Tang JL, Zhang B, Xu JP, Qi L, Xin D, Wang L, Wang BZ, Tian YT, Li Y, Huang J. Tang JL, et al. Among authors: huang j. Cancer Med. 2023 Mar;12(5):5639-5648. doi: 10.1002/cam4.5414. Epub 2022 Nov 7. Cancer Med. 2023. PMID: 36341590 Free PMC article.

5

Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial.

Huang J, Xiao J, Fang W, Lu P, Fan Q, Shu Y, Feng J, Zhang S, Ba Y, Zhao Y, Liu Y, Bai C, Bai Y, Tang Y, Song Y, He J. Huang J, et al. Cancer Med. 2021 Mar;10(5):1681-1689. doi: 10.1002/cam4.3771. Epub 2021 Feb 14. Cancer Med. 2021. PMID: 33586360 Free PMC article. Clinical Trial.

6

Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China.

Huang J, Mo H, Zhang W, Chen X, Qu D, Wang X, Wu D, Wang X, Lan B, Yang B, Wang P, Zhang B, Yang Q, Jiao Y, Xu B. Huang J, et al. Cancer. 2019 Mar 1;125(5):742-749. doi: 10.1002/cncr.31855. Epub 2018 Dec 3. Cancer. 2019. PMID: 30508306 Free article. Clinical Trial.

7

Plasma cytokines interleukin-18 and C-X-C motif chemokine ligand 10 are indicative of the anti-programmed cell death protein-1 treatment response in lung cancer patients.

Wang Y, Chen H, Zhang T, Yang X, Zhong J, Wang Y, Chi Y, Wu M, An T, Li J, Zhao X, Dong Z, Wang Z, Zhao J, Zhuo M, Huang J. Wang Y, et al. Among authors: huang j. Ann Transl Med. 2021 Jan;9(1):33. doi: 10.21037/atm-20-1513. Ann Transl Med. 2021. PMID: 33553326 Free PMC article.

8

HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial.

Song Y, Li N, Li Q, Liang X, Zhang S, Fan Q, Yin X, Zhuang Z, Liu Y, Zhang J, Kou X, Zhong H, Wang X, Dou Y, Huang J. Song Y, et al. Among authors: huang j. J Immunother Cancer. 2020 Oct;8(2):e001279. doi: 10.1136/jitc-2020-001279. J Immunother Cancer. 2020. PMID: 33060149 Free PMC article. Clinical Trial.

9

Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.

Zhang B, Qi L, Wang X, Xu J, Liu Y, Mu L, Wang X, Bai L, Huang J. Zhang B, et al. Among authors: huang j. Cancer Commun (Lond). 2020 Dec;40(12):711-720. doi: 10.1002/cac2.12119. Epub 2020 Dec 12. Cancer Commun (Lond). 2020. PMID: 33314747 Free PMC article. Clinical Trial.

10

The efficacy and safety of nanoparticle albumin bound-paclitaxel-based regimen as second- or third-line treatment in patients with advanced esophageal squamous cell carcinoma.

Xin D, Song Y, Mu L, Zhang B, Qi L, Gao J, Wang X, Xu J, Qu T, Huang J. Xin D, et al. Among authors: huang j. Thorac Cancer. 2023 May;14(15):1392-1397. doi: 10.1111/1759-7714.14885. Epub 2023 Apr 10. Thorac Cancer. 2023. PMID: 37035870 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

53,491 results

Search Page